

- Jian xu, PHD April 12 2022







China IP SME Helpdesk

ABOUT US

Helpdesk Free Services

Enquiry Helpline



question@china-iprhelpdesk.eu

Training Workshops



Webinars



Website & Blog



https://ec.europa.eu/ip-helpdesk

Guides & Factsheets




One-on-one Consultation Sessions











https://eu.europa.eu/ip-helpdesk





BRIEF BIO OF JIAN XU



- Dually qualified Chinese lawyer and patent/trademark attorney, started practicing China IP law from 2006.
- Heading up the IP prosecution practice of Gowling WLG China
- Handled all aspects of IP in business including drafting, prosecution, enforcement, acquisition and licensing of patents, trademarks and brand, design rights, copyright and content.
- Author of the book: "Chinese Intellectual Property A Practitioner's Guide".
- Contact: <u>Jian.Xu@gowlingwlg.com</u>; Linkedln: https://www.linkedin.com/in/xujian/





Topics

- > China patent law changes in 2021
- China copyright law changes in 2021
- ➤ China trademark updates in 2021
- China's 15-year IP PlanIllustrated with high profile IP cases





China Patent Law Changes in 2021








01 Partial Designs

Partial design allowed:

- PR In line with international practice
- IPR Must be based on a product
- PR Expanding the protection scope
- IPR Cost savings for series of products







02 | Hague System for Designs



IPR China has joined the Hague System.

IPR Protection term for designs extended to 15 years.

IPR Similar to Madrid system for trademarks


PR One international application to WIPO, designating China.

IPR Up to 100 designs in one application





03 | Pharmaceutical Patents



3.1

Pharmaceutical patent term extension

IPR Total compensation period: maximum 5 years

PR For new drugs after obtaining FDA approval: maximum effective patent term 14 years

3.2

Pharmaceutical patent linkage system

- IPR Linking "FDA approval of drugs" with "pharmaceutical patent infringement lawsuit"
- IPR A full system similar to the US system (Hatch-Waxman Act)
- IPR Innovator: list your drug patents in CFDA and sue generics for patent infringement during FDA approval
- IPR Generics: challenge innovator's patents and enjoy market exclusivity





Chugai vs. Haihe

The first pharmaceutical patent linkage lawsuit

In November 2021, the Beijing IP Court received the first pharmaceutical patent linkage lawsuit in China.



<u>Plaintiff</u>

Japanese Chugai, is the market authorisation holder of the listed patented drug "Eldecalcitol Soft Capsule", and owns Chinese invention patent entitled "ED-71 preparation" with the patent number 2005800098777.6.)



Defendant

Haihe, applied to China FDA for approval of the generic drug identically named "Eldecalcitol Soft Capsule", and stated that the generic drug does not fall within the scope of the Chugai patent





Chugai sued Haihe for patent infringement before the Beijing IP Court, under the pharmaceutical patent linkage provision.





04 Patent Damages

- 4.1
- Punitive damages up to five times the original damages
- IPR The "intentional" and "serious" elements
- IPR Deterrent value
- 4.2
- Increasing statutory damages to RMB five million (c.a. EUR 71,900)
- IPR Judge's discretion
- IPR Employed in most cases
- 4.3
- Evidence disclosure obligation relating to damage calculation





CATL v. TAFEL

- Utility model patent winning a damage award of RMB 23.3 million
- In CATL vs. TAFEL, the utility model patent relates to an explosion-proof device for the top cover of a secondary battery.

This utility model, with a relatively wide scope of claims, is the early-preferred solution for the explosion-proof sheet structure under the top cover mechanism.



Furthermore, the patent is not easy to invalidate due to the low inventiveness requirement for a utility model.



In August 2021, CATL received a favourable judgement based on in its utility model patent infringement action against TAFEL, and was awarded damages of RMB 23.3 million.





05 Other Notable Changes



5.1

Open license system

A patentee may express in writing to CNIPA its willingness to license their patents to anyone and specify relevant royalties and method of payment. CNIPA will announce the patentee's statement and offer the open license.

5.2

Patent term compensation due to delays in examination

IPR If a patent application has been pending for more than 4 years since the filing date, or more than 3 years since the request for substantive examination, the applicant is entitled to request patent term compensation due to the delay in patent examination

5.3

Administrative protection of patents

- IPR Increased fine for patent passing-off
- IPR CNIPA will have authority to deal with nation-wide patent infringement cases.





Casio vs. Guangzhou company


Administrative mediation of a patent infringement case with a compensation amount of RMB 1.7 million



In 2020, Casio discovered watches made and sold by a Guangzhou company allegedly infringing two of Casio's design patents



Casio submitted an administrative patent infringement complaint to the Guangzhou IP Office



In August 2021, both parties signed an administrative mediation agreement to reach a settlement

- Compensation of RMB 1.7 million,
- Undertaking to immediately stop manufacturing
- Undertaking to stop selling and offering for sale the infringing products.





China Copyright Law Changes in 2021







06 Copyright Damages



6.1 Increasing the statutory damage to a maximum of RMB 5 million;

6.2 Mandating the minimum statutory damage is RMB 500

6.3 Introducing punitive damages up to five times the original damage





06 Copyright Damages



- Changing the definition of copyright works as " intellectual creations with originality in the realm of literature, art or science that can be represented in a certain form ";
- Defining a broad category of " audio-visual works " covering all forms of movie-analogous works
- Specifying that the collective copyright management body is a non-profit organisation; and
- **6.7** Improving the accessibility of copyright works for person with dyslexia





Tencent vs. Yinxun

Identifying the author of copyright for AI generated works



- January 2021, China's first case of copyright dispute over AI generated article works
- Tencent created an AI writing tool called "Dreamwriter", and found that Yinxun copied articles created by Dreamwriter
- Can Dreamwriter be deemed as the author/creator of those articles
 - The court said "no". AI is only a tool assisting the creation, and not the genuine author of the work.
- Can the articles be deemed as copyright works
 - The court said "yes". The works meet the originality standard.
- Who is the copyright owner for those articles
 - Those are service works, so Tencent is the copyright owner.





China Trade Mark Law Changes in 2021







07 Combating Bad Faith Trade Mark Filings

- 7.1 Special Action Plan for Cracking down on Malicious Preemptive Trade mark Registration March 2021
- 7.2 CNIPA proactively revoked 482,000 pieces of bad faith trade mark filings in 2021
- **7.3** Specific measures include:
 - IPR Blacklist system
 - IPR Proactive refusal of clearly bad faith filings
- PR Flexible evidence standard for determining bad faith
- IPR Emphasis on intention to use





Lego vs. Le Pin



High damage awards for blatant trademark infringement and unfair competition



In March 2021, Guangdong High Court issued a final judgment in the case of "LEGO" v. "Le Pin", finding that "Le Pin" manufacturers have constituted trademark infringement and unfair competition, and ordered a damage award of RMB 30 million (c.a. EUR 3.9 million).



The court found that Le Pin had been copying LEGO toys for four years, infringing on eight registered trademarks and one influential trade name of LEGO.





Why did the court accepted the full amount of claimed damage by Lego

- According to a relevant prior criminal judgment, Le Pin's illegal business turnover reached RMB 330 million from September 2017 to April 2019.
- Based on the sales data of "Le Pin" provided by E-commerce platform Taobao, Le Pin's illegal business turnover exceeded RMB 500 million.
- Referencing reasonable industry profitability level, the illegal profit is about RMB 160 million.





China's 15-year IP Plan







Quantifiable Goals - by 2025



- 7.1 The added value of *patent intensive industries* will account for *13% of GDP*
- 7.2 The added value of *copyright industries* will account for *7.5% of GDP*,
- The annual total import and export of <u>intellectual property royalties</u> will reach <u>350 billion RMB</u>, and
- 7.4 The number of <u>high-value invention patents per 10,000 people will reach 12.</u>





08 Outlook for 2022



- The Chinese courts are going to apply more punitive damages in IP infringement cases.
- China is going to shift from quantity driven to quality driven in term of its patent filings.
- 8.3 China will continue to take a tough stance in striking down bad faith trademark filings.
- Pharmaceutical companies, both innovators and generics, are going to test out China's pharmaceutical patent linkage system.





Questions?

HELPLINE

free, fast & confidential

3 days

question@china-iprhelpdesk.eu



Your feedback is very valuable info for us.

We appreciate if you could share your comments with us.





Stay connected!









ChinaIPRSMEHelpdesk



https://ec.europa.eu/ip-helpdesk



